Hartal-Benishay L, Tal S, Elkader A, Ehsainieh O, Srouji-Eid R, Lavy T
iScience. 2024; 27(12):111403.
PMID: 39687029
PMC: 11647142.
DOI: 10.1016/j.isci.2024.111403.
Susilawati E, Levita J, Susilawati Y, Sumiwi S
Front Pharmacol. 2023; 14:1281150.
PMID: 38044940
PMC: 10690608.
DOI: 10.3389/fphar.2023.1281150.
Ali G, Islam N, Qaim M, Ullah R, Jan M, Shabbiri K
Inflammopharmacology. 2023; 32(1):643-656.
PMID: 37864684
DOI: 10.1007/s10787-023-01356-0.
de Oliveira D, Maia R, de Carvalho Franca P, Fernandes P, Barbosa G, Lima L
Pharmaceuticals (Basel). 2022; 15(12).
PMID: 36558970
PMC: 9781268.
DOI: 10.3390/ph15121519.
Mori T, Abe I
Beilstein J Org Chem. 2022; 18:707-721.
PMID: 35821691
PMC: 9235837.
DOI: 10.3762/bjoc.18.71.
GC-MS Analysis and Various In Vitro and In Vivo Pharmacological Potential of Lindl.
Mahnashi M, Alqahtani Y, Alyami B, Alqarni A, Ahmed Alshrahili M, Abou-Salim M
Evid Based Complement Alternat Med. 2022; 2022:7921408.
PMID: 35399645
PMC: 8989558.
DOI: 10.1155/2022/7921408.
Structural Modifications Yield Novel Insights Into the Intriguing Pharmacodynamic Potential of Anti-inflammatory Nitro-Fatty Acids.
Hellmuth N, Brat C, Awad O, George S, Kahnt A, Bauer T
Front Pharmacol. 2021; 12:715076.
PMID: 34867322
PMC: 8637440.
DOI: 10.3389/fphar.2021.715076.
Mollusc-Derived Brominated Indoles for the Selective Inhibition of Cyclooxygenase: A Computational Expedition.
Rahman M, Junaid M, Hosen S, Mostafa M, Liu L, Benkendorff K
Molecules. 2021; 26(21).
PMID: 34770946
PMC: 8587571.
DOI: 10.3390/molecules26216538.
In Vitro and In Silico Evaluation of New 1,3,4-Oxadiazole Derivatives of Pyrrolo[3,4-]pyridazinone as Promising Cyclooxygenase Inhibitors.
Peregrym K, Szczukowski L, Wiatrak B, Potyrak K, Czyznikowska Z, Swiatek P
Int J Mol Sci. 2021; 22(17).
PMID: 34502040
PMC: 8431030.
DOI: 10.3390/ijms22179130.
Learning from Nature: From a Marine Natural Product to Synthetic Cyclooxygenase-1 Inhibitors by Automated De Novo Design.
Friedrich L, Cingolani G, Ko Y, Iaselli M, Miciaccia M, Perrone M
Adv Sci (Weinh). 2021; 8(16):e2100832.
PMID: 34176236
PMC: 8373093.
DOI: 10.1002/advs.202100832.
Three-dimensional structure of human cyclooxygenase (hCOX)-1.
Miciaccia M, Belviso B, Iaselli M, Cingolani G, Ferorelli S, Cappellari M
Sci Rep. 2021; 11(1):4312.
PMID: 33619313
PMC: 7900114.
DOI: 10.1038/s41598-021-83438-z.
Identification of Active Compounds From Yi Nationality Herbal Formula Influencing COX-2 and VCAM-1 Signaling.
Zhang J, Chen X, Wu Y, Li L, Huang L, Yin Q
Front Pharmacol. 2021; 11:568585.
PMID: 33442381
PMC: 7797783.
DOI: 10.3389/fphar.2020.568585.
Specificity Distorted: Chemical Induction of Biological Paracatalysis.
Callahan B, Ciulla D, Wagner A, Xu Z, Zhang X
Biochemistry. 2020; 59(38):3517-3522.
PMID: 32931253
PMC: 7558459.
DOI: 10.1021/acs.biochem.0c00643.
Structural and Chemical Biology of the Interaction of Cyclooxygenase with Substrates and Non-Steroidal Anti-Inflammatory Drugs.
Rouzer C, Marnett L
Chem Rev. 2020; 120(15):7592-7641.
PMID: 32609495
PMC: 8253488.
DOI: 10.1021/acs.chemrev.0c00215.
A New Look at the Structures of Old Sepsis Actors by Exploratory Data Analysis Tools.
Gnoni A, De Nitto E, Scacco S, Santacroce L, Palese L
Antibiotics (Basel). 2019; 8(4).
PMID: 31739644
PMC: 6963771.
DOI: 10.3390/antibiotics8040225.
Arg-513 and Leu-531 Are Key Residues Governing Time-Dependent Inhibition of Cyclooxygenase-2 by Aspirin and Celebrex.
Dong L, Anderson A, Malkowski M
Biochemistry. 2019; 58(38):3990-4002.
PMID: 31469551
PMC: 8103790.
DOI: 10.1021/acs.biochem.9b00659.
Interactions of fatty acids, nonsteroidal anti-inflammatory drugs, and coxibs with the catalytic and allosteric subunits of cyclooxygenases-1 and -2.
Smith W, Malkowski M
J Biol Chem. 2019; 294(5):1697-1705.
PMID: 30710016
PMC: 6364783.
DOI: 10.1074/jbc.TM118.006295.
Residual cyclooxygenase activity of aspirin-acetylated COX-2 forms 15 R-prostaglandins that inhibit platelet aggregation.
Gimenez-Bastida J, Boeglin W, Boutaud O, Malkowski M, Schneider C
FASEB J. 2018; 33(1):1033-1041.
PMID: 30096040
PMC: 6355089.
DOI: 10.1096/fj.201801018R.
Design and Synthesis of Aza-/Oxa Heterocycle-Based Conjugates as Novel Anti-Inflammatory Agents Targeting Cyclooxygenase-2.
Kaur S, Kumari P, Singh G, Bhatti R, Singh P
ACS Omega. 2018; 3(5):5825-5845.
PMID: 30023927
PMC: 6044720.
DOI: 10.1021/acsomega.8b00445.
Dual cyclooxygenase-fatty acid amide hydrolase inhibitor exploits novel binding interactions in the cyclooxygenase active site.
Goodman M, Xu S, Rouzer C, Banerjee S, Ghebreselasie K, Migliore M
J Biol Chem. 2018; 293(9):3028-3038.
PMID: 29326169
PMC: 5836124.
DOI: 10.1074/jbc.M117.802058.